Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

This study has been completed.
Food and Drug Administration (FDA)
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Ryan Vandrey, Johns Hopkins University Identifier:
First received: April 30, 2009
Last updated: December 3, 2013
Last verified: December 2013
Heavy marijuana users report experiencing trouble sleeping when they try to quit, but this has not been carefully studied. This research is being done to learn more about sleep function in heavy marijuana users, and to determine whether a medication approved for treating insomnia can help restore normal sleep function during brief periods of abstinence.

Condition Intervention Phase
Marijuana Dependence
Drug: eszopiclone
Drug: Placebo
Drug: ramelteon
Drug: zolpidem
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

Resource links provided by NLM:

Further study details as provided by Ryan Vandrey, Johns Hopkins University:

Primary Outcome Measures:
  • Marijuana Withdrawal [ Time Frame: Every day during study participation ]

Secondary Outcome Measures:
  • Objective Sleep Assessment [ Time Frame: Every day during study participation ]
  • Cognitive Performance [ Time Frame: Every day during study participation ]

Enrollment: 36
Study Start Date: October 2008
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active Medication
Participants receive active hypnotic medication prior to sleep
Drug: eszopiclone
Oral capsule at dose recommended for adults
Drug: ramelteon
Drug: zolpidem
Placebo Comparator: Placebo
Participants receive placebo prior to sleep
Drug: Placebo
Participants receive placebo prior to sleep


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • current use of marijuana
  • able to give informed consent

Exclusion Criteria:

  • dependence on drug other than marijuana
  • current sleep disorder
  • pregnant, breast feeding, or planning to become pregnant within the next 3 months
  • currently seeking treatment for cannabis-related problems or otherwise trying to reduce use
  • use of cannabis under the guidance of a physician for a medical disorder
  • unstable or uncontrolled cardiovascular disease (e.g., hypertension, angina)
  • allergy to study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00893269

United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Johns Hopkins University
Food and Drug Administration (FDA)
National Institute on Drug Abuse (NIDA)
Principal Investigator: Ryan Vandrey, Ph.D. Johns Hopkins University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ryan Vandrey, Associate Professor, Johns Hopkins University Identifier: NCT00893269     History of Changes
Other Study ID Numbers: NA_00017909
R21DA025794 ( US NIH Grant/Contract Award Number )
Study First Received: April 30, 2009
Last Updated: December 3, 2013

Keywords provided by Ryan Vandrey, Johns Hopkins University:

Additional relevant MeSH terms:
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017